RT Journal Article
SR Electronic
T1 Financial toxicity in ovarian cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP ijgc-2022-003594
DO 10.1136/ijgc-2022-003594
A1 Allison L Swiecki-Sikora
A1 Amaranta D Craig
A1 Christina S Chu
YR 2022
UL http://ijgc.bmj.com/content/early/2022/08/19/ijgc-2022-003594.abstract
AB Ovarian cancer is the most costly and deadly of the gynecologic malignancies. Financial toxicity from out-of-pocket costs for direct care and medications as well as indirect costs from lost income is a growing challenge in oncology. The aim of this review is to focus on recent financial toxicity literature in the gynecologic oncology sphere and highlight specific issues and challenges regarding financial toxicity in ovarian cancer. Treatment options for ovarian cancer lead to variable costs for patients, and there are risk factors for high financial toxicity unique to gynecologic oncology patients. Identification and prompt intervention for those most at risk can help alleviate financial distress from ovarian cancer care.